“‘Un giorno’ è adesso!”: Anpac Bio & Med Partners celebra il ‘Mese nazionale per la prevenzione del cancro’ superando a 60.000 casi di ‘Biopsia liquida’

Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)

  • Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)

SACRAMENTO, California--()--Anpac Bio-Medical Science Company (Anpac Bio) e i suoi partner e ospedali per la ricerca medica acclamati a livello internazionale, stanno celebrando la “Giornata mondiale contro il cancro” (#WorldCancerDay) e il “Mese nazionale per la prevenzione del cancro” (#NationalCancerPreventionMonth) superando una pietra miliare nuova e globale: processare oltre 60.000 casi corroborati indipendentemente di test di biopsia liquida “Analisi per la differenziazione del cancro” (Cancer Differentiation Analysis, CDA) in tutto il mondo.

Famosi nel mondo, la Second Military Medical University e la sua associata lo Changhai Hospital (CH) a Shanghai, Cina, hanno condotto oltre 4.000 test sulla biopsia liquida per la CDA dal 2014.

Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.

Contacts

Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
Drisha_Leggitt@AnpacBio.com

Contacts

Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
Drisha_Leggitt@AnpacBio.com